Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/19/2025

Dobutamine Therapy

Introduction to Dobutamine

  • Dobutamine is a synthetic inotropic agent that acts primarily through stimulation of β1-receptors and β2-receptors to produce dose-dependent positive inotropic and chronotropic effects, resulting in reduced vascular resistance 2
  • The European Society of Cardiology recommends dobutamine as a treatment option for patients with heart failure, with peak dose effects typically occurring at 10-15 μg/kg/min, and maximum hemodynamic effects seen at this dosage range 1

Dosage and Administration

  • Low doses of dobutamine (2-5 μg/kg/min) induce mild arterial vasodilation, augment stroke volume, decrease pulmonary wedge and central venous pressures, and have a minimal effect on heart rate 2
  • Moderate doses of dobutamine (5-10 μg/kg/min) significantly increase cardiac output, moderately increase stroke volume, and significantly increase aortic dp/dt, with a moderate increase in heart rate 2
  • High doses of dobutamine (>10 μg/kg/min) produce a maximum inotropic effect, a more pronounced chronotropic effect, may cause vasoconstriction, and increase the risk of arrhythmias 1, 2
  • Patients receiving beta-blockers may require higher doses of dobutamine (up to 20 μg/kg/min) to restore its inotropic effect, as recommended by the European Journal of Heart Failure 1

Special Considerations

  • Dobutamine may increase ventricular response rate in patients with atrial fibrillation due to facilitation of atrioventricular conduction, according to the European Heart Journal 2
  • Prolonged infusion of dobutamine (more than 24-48 hours) is associated with tolerance and partial loss of hemodynamic effects, as reported by the European Heart Journal 2
  • Higher doses of dobutamine increase the risk of tachycardia, arrhythmias, and myocardial ischemia, as warned by the European Heart Journal and European Journal of Heart Failure 1, 2

Discontinuation and Comparison to Other Agents

  • When discontinuing dobutamine, a gradual tapering approach is recommended, with a decrease in dosage by steps of 2 μg/kg/min every other day, and simultaneous optimization of oral vasodilator therapy, as advised by the European Heart Journal 2
  • Dobutamine differs from other inotropic agents, such as isoproterenol and dopamine, in its effects on heart rate, peripheral vascular resistance, and cardiac output, as described by the European Heart Journal 2